2019 年第 8 期 第 14 卷

卡维地洛联合丹参酮ⅡA磺酸钠对心力衰竭患者心脏重构的影响

Effect of carvedilol combined with sodium tanshinone ⅡA sulfonate on cardiac remodeling in patients with heart failure

作者：崔振川郭静狄宁宁周松

英文作者：

单位：054000河北省邢台市第三医院心内科二病区（崔振川、狄宁宁、周松）,放射科（郭静）

英文单位：

关键词：心力衰竭；卡维地洛；丹参酮ⅡA磺酸钠；心脏重构

英文关键词：

• 摘要：

• 【摘要】目的    观察卡维地洛联合丹参酮ⅡA磺酸钠对心力衰竭患者心脏重构的影响。方法    选取2016年12月至2018年7月河北省邢台市第三医院收治的心力衰竭患者160例为研究对象。完全随机分为对照组和观察组，各80例。对照组患者采用常规方法治疗；观察组患者在对照组的基础上给予卡维地洛联合丹参酮ⅡA磺酸钠治疗。观察治疗前后2组患者的心功能、心肌重构指标、血清中心肌重构相关蛋白水平的变化。结果    治疗后，2组患者心排血量、每搏输出量均大于治疗前，且观察组大于对照组［（6.5±1.2）L/min比（5.9±1.1）L/min、（84±13）ml比（70±10）ml］；左心房舒张末期内径、左心室舒张末期内径、左心室后壁厚度、室间隔厚度和左心室心肌质量指数、基质金属蛋白酶2、基质金属蛋白酶9、基质金属蛋白酶组织抑制因子1水平均小于/低于治疗前，且观察组小于/低于对照组，差异均有统计学意义（均P<0.05）。结论    卡维地洛联合丹参酮ⅡA磺酸钠能有效改善心力衰竭患者心功能、抑制心肌重构。

• 【Abstract】Objective    To observe the effect of carvedilol combined with sodium tanshinone ⅡA sulfonate on cardiac remodeling in patients with heart failure. Methods    Totally 160 patients with heart failure admitted to Xingtai Third Hospital, Hebei Province from December 2016 to July 2018 were randomly divided into control group and observation group, with 80 cases in each group. The control group was treated with routine therapy; the observation group was treated with carvedilol combined with sodium tanshinone ⅡA sulfonate on the basis of routine therapy. Cardiac function, cardiac remodeling indexes and levels of serum cardiac remodeling-related proteins were analyzed. Results    There were no significant differences of cardiac function, myocardial remodeling indexes and myocardial remodeling-related protein levels between groups before treatment(all P>0.05). After treatment, cardiac output and stroke output were significantly improved in both groups and the indexes in observation group were higher than those in control group［（6.5±1.2）L/min vs （5.9±1.1）L/min, （84±13）ml vs （70±10）ml］; left atrial end-diastolic diameter, left ventricular end-diastolic diameter, left ventricular posterior wall thickness, interventricular septum thickness, left ventricular myocardial mass index, serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 significantly decreased in both groups and they were lower in observation group than those in control group(all P<0.05). Conclusion    Carvedilol combined with sodium tanshinone ⅡA sulfonate can effectively improve cardiac function and inhibit myocardial remodeling in patients with heart failure.